Table 1:
ACIP Recommendations for Influenza Vaccination (1)
Persons greater than age 50
Children age 6 months – 18 years
Persons with any one of the following
Underlying medical conditions
Pregnant
Healthcare workers
Household contacts of high risk patients
Table 2: Influenza Vaccines Available in the United States, 2008-2009.
|
Vaccine |
Trade Name |
Manufacturer |
Approved Age |
Mercury Content |
Route |
|
|
|
|
|
μg per 0.5 ml |
|
|
LA/IV |
FluMist |
Medimmune |
2-49 yr (healthy persons) |
0 |
intranasal |
|
TIV |
Fluzone |
Sanofi Pasteur |
> 6 mo |
25 (multidose vial); 0 (single-dose prefilled syringe) |
intramuscular |
|
TIV |
Fluvirin |
Novartis Vaccines |
> 4 yr |
25.4 (multidose vial); 0 (single-dose prefilled syringe) |
intramuscular |
|
TIV |
Fluarix |
GlaxoSmithKline |
> 18 yr |
<1.0 (single-dose prefilled syringe) |
intramuscular |
|
TIV |
FluLaval |
GlaxoSmithKline |
> 18 yr |
25 (multidose vial) |
intramuscular |
|
TIV |
Afluria |
CSL Biotherapies |
> 18 yr |
25 (multidose vial); 0 (single-dose prefilled syringe) |
intramuscular |
Reprinted from Glezen WP, NEJM 2008 (5)
Table 3: Antiviral Agents for Treatment of and Prophylaxis against Influenza
|
Drug |
Formulation |
Adult Dose |
Common Side Effects |
|
|
|
|
Treatment |
Prophylaxis |
|
|
Oseltamivir (Tamiflu, Roche) |
75-mg capsule |
1 capsule twice a day for 5 days |
1 capsule/day |
Nausea, vomiting |
|
Zanamivir (Relenza, GlaxoSmithKline) |
5 mg per inhalation (Diskhaler) |
2 inhalations twice a day for 5 days |
2 inhalations/day |
Bronchospasm |
|
Amantadine (Symmetrel, Endo Pharmaceuticals) |
100-mg tablet |
1 tablet twice a day for 3-5 days |
1 table/day |
CNS effects: seizures, insomnia |
|
Rimantadine (Flumadine, Forst Laboratories) |
100-mg tablet |
1 tablet twice a day for 5 days |
1 tablet/day |
_ |
|
Ribavirin (Virazole, Valeant Pharmaceuticals) |
60 mg/ml in reservoir |
Aerosol for 2 hr every 8 hr for 5 days or as indicated |
Not applicable |
_ |
Reprinted from Glezen WP, NEJM 2008 (5)